A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
NCT ID: NCT05721235
Last Updated: 2025-09-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
123 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-06-02
Study Completion Date
2025-08-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
NCT05685732
Attention Deficit/Hyperactivity Disorder
COMPLETED
PHASE4
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
NCT06000501
Adult Attention Deficit Hyperactivity Disorder
COMPLETED
PHASE4
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
NCT02677519
Attention Deficit Disorder With Hyperactivity
UNKNOWN
PHASE4
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
NCT00301236
ADHD, ADD
COMPLETED
PHASE3
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
NCT05924594
ADHD
ADHD - Combined Type
Attention Deficit Hyper Activity
+4 more
SUSPENDED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• Screening Period: New subjects will undergo a Screening Period up to 30 days prior to entering the Dose Optimization Phase.
• Dose Optimization Phase: During the 3-week Dose Optimization Phase, subjects will start at 13.1 mg/2.6 mg, and may be titrated to doses of 26.1 mg/5.2 mg or 39.2 mg/7.8 mg Azstarys® capsules based on individual tolerability and best dose-response in the opinion of the Investigator.
• Treatment Phase: Eligible subjects will receive single daily doses of Azstarys® for approximately 360 ±20 days (approximately 12 months). The starting dose of Azstarys® in the Treatment Phase will be the same as the optimized dose of Azstarys® at the end of the Dose Optimization Phase, either 13.1 mg/2.6 mg, 26.1/5.2 mg, or 39.2 mg/7.8 mg per day. The daily dose may be changed at any time to any of the allowed dose levels (13.1 mg/2.6 mg, 26.1/5.2 mg, or 39.2 mg/7.8 mg per day) at the Investigator' discretion, based on individual tolerability and dose response.
• Dose Optimization Phase: During the 3-week Dose Optimization Phase, subjects will start at 13.1 mg/2.6 mg, and may be titrated to doses of 26.1 mg/5.2 mg or 39.2 mg/7.8 mg Azstarys® capsules based on individual tolerability and best dose-response in the opinion of the Investigator.
• Treatment Phase: Eligible subjects will receive single daily doses of Azstarys® for approximately 360 ±20 days (approximately 12 months). The starting dose of Azstarys® in the Treatment Phase will be the same as the optimized dose of Azstarys® at the end of the Dose Optimization Phase, either 13.1 mg/2.6 mg, 26.1/5.2 mg, or 39.2 mg/7.8 mg per day. The daily dose may be changed at any time to any of the allowed dose levels (13.1 mg/2.6 mg, 26.1/5.2 mg, or 39.2 mg/7.8 mg per day) at the Investigator' discretion, based on individual tolerability and dose response.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Attention Deficit/Hyperactivity Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
The primary objective is to determine the safety and tolerability for up to 12 months of treatment with Azstarys based on incidence of adverse events
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label
13.1 mg/2.6 mg SDX/d-MPH, 26.1/5.2 mg SDX/d-MPH, or 39.2 mg/7.8 mg SDX/d-MPH
Group Type
EXPERIMENTAL
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Intervention Type
DRUG
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. New Subjects must be at least 4 years old and less than 5 years and 10 months old at Screening.
2. Subjects must have a body weight within the 5th and 95th percentile according to the gender-specific weight-for-age percentile charts from the Centers for Disease Control and Prevention (CDC).
3. Subject must be in general good health defined as the absence of any clinically relevant abnormalities as determined by the Investigator based on physical examinations, vital signs, ECGs, medical history, and clinical laboratory values (chemistry, hematology and urinalysis) at Screening.
4. At least one parent/legal guardian of the subject must voluntarily give written permission for the subject to participate in the study.
5. Subject must meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactive/impulsive presentation) per clinical evaluation and confirmed by the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI Kid).
6. Subject must have had ADHD symptoms present for at least 6 months prior to the Screening Visit.
7. Subject must be able and willing to wash out current stimulant ADHD medications, including herbal medications from 5 days prior to the start of the Dose Optimization Phase, and abstain from taking these to the end of the Treatment Phase (Visit 17) or Early Termination (ET); and wash out non-stimulant ADHD medications from 14 days prior to the start of the Dose Optimization Phase, and abstain from taking these to the end of the Treatment Phase (Visit 17) or ET.
8. Subject must have a score of ≥4 (Moderately Ill) on the clinician-administered Clinical Global Impressions-Severity (CGI-S) scale.
9. Subject functions at an age-appropriate level intellectually, as determined by the Investigator.
10. Subject must have age and sex adjusted ratings of ≥90th percentile Total Score on the ADHD-RS-IV (Preschool Version) rated over the past 6 months.
11. Subject must have a systolic and diastolic blood pressure below the 95th percentile for age, and gender according to the 2017 AAP guidelines (Flynn 2017) based on the average of 3 measurements 2-5 minutes apart.
12. Subject's parent/legal guardian and caregiver (if applicable) must understand and be willing and able to comply with all study procedures and visit schedule.
13. Subject's parent/legal guardian, and caregiver (if applicable) must be able to speak and understand English or Spanish and be able to communicate satisfactorily with the Investigator and study coordinator.
2. Subjects must have a body weight within the 5th and 95th percentile according to the gender-specific weight-for-age percentile charts from the Centers for Disease Control and Prevention (CDC).
3. Subject must be in general good health defined as the absence of any clinically relevant abnormalities as determined by the Investigator based on physical examinations, vital signs, ECGs, medical history, and clinical laboratory values (chemistry, hematology and urinalysis) at Screening.
4. At least one parent/legal guardian of the subject must voluntarily give written permission for the subject to participate in the study.
5. Subject must meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactive/impulsive presentation) per clinical evaluation and confirmed by the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI Kid).
6. Subject must have had ADHD symptoms present for at least 6 months prior to the Screening Visit.
7. Subject must be able and willing to wash out current stimulant ADHD medications, including herbal medications from 5 days prior to the start of the Dose Optimization Phase, and abstain from taking these to the end of the Treatment Phase (Visit 17) or Early Termination (ET); and wash out non-stimulant ADHD medications from 14 days prior to the start of the Dose Optimization Phase, and abstain from taking these to the end of the Treatment Phase (Visit 17) or ET.
8. Subject must have a score of ≥4 (Moderately Ill) on the clinician-administered Clinical Global Impressions-Severity (CGI-S) scale.
9. Subject functions at an age-appropriate level intellectually, as determined by the Investigator.
10. Subject must have age and sex adjusted ratings of ≥90th percentile Total Score on the ADHD-RS-IV (Preschool Version) rated over the past 6 months.
11. Subject must have a systolic and diastolic blood pressure below the 95th percentile for age, and gender according to the 2017 AAP guidelines (Flynn 2017) based on the average of 3 measurements 2-5 minutes apart.
12. Subject's parent/legal guardian and caregiver (if applicable) must understand and be willing and able to comply with all study procedures and visit schedule.
13. Subject's parent/legal guardian, and caregiver (if applicable) must be able to speak and understand English or Spanish and be able to communicate satisfactorily with the Investigator and study coordinator.
Exclusion Criteria
1. Subject with any clinically significant chronic medical condition that, in the judgment of the Investigator, may interfere with the participant's ability to participate in the study.
2. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances.
3. Subject has generalized anxiety disorder or panic disorder that has been the primary focus of treatment at any time during the 12 months prior to Screening, or that has required pharmacotherapy any time during the 6 months prior to Screening.
4. Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood (e.g., Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders), or history of persistent neurological symptoms attributable to serious head injury.
5. Subject taking anticonvulsants for seizure control currently or within the past 2 years before Screening are not eligible for study participation.
6. Subject has a current (last month) psychiatric diagnosis other than specific phobia, motor skills disorders, ODD, sleep disorders, elimination disorders, adjustment disorders, learning disorders, or communication disorders.
7. In the opinion of the Investigator, subject has clinically significant suicidal ideation/behavior, based on history of attempted suicide and the C-SSRS assessment at Screening.
8. Subject has any clinically significant unstable medical abnormality, chronic disease (including asthma or diabetes), or a history of a clinically significant abnormality of the cardiovascular (including cardiomyopathy, serious arrhythmias, structural cardiac disorders, or severe hypertension), gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion of study drug.
9. Subject has a history or presence of abnormal ECGs, which in the Investigator's opinion is clinically significant.
10. Subject has a history of, or currently has a malignancy.
11. Subject has uncontrolled thyroid disorder as evidenced by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the upper limit of normal (ULN) for the reference laboratory at Screening.
12. Subject has greater than trace proteinuria on the urinalysis at Screening.
13. A current or recent (past 12 months) history of drug abuse in someone living in the subjects' home.
14. Subject has a positive urine screen for drugs of abuse at Screening. If the urine test is positive for any of the analytes at Screening, the subject will be excluded from study participation, with the exception of the following: Depending on a subject's current ADHD medication at Screening, the urine screen may test positive for MPH for treatment of their ADHD.
15. Subject has participated in any other clinical study with an investigational drug/product within 30 days or at least 5 half-lives, whichever is longer, prior to Screening, except for participation in Study KP415.P01.
16. Subject has taken ADHD medications from more than one class within 30 days prior to Screening. Subjects on a stable dose of one ADHD medication with occasional use of ADHD medications from another class are eligible at the discretion of the Investigator.
17. Subject has demonstrated lack of response or intolerability to adequate dose and duration of treatment with methylphenidate products.
18. Subject is using or planning to use prohibited drugs during the trial as specified in the protocol.
19. Subject is planning to initiate psychotherapy during the study (subjects participating in psychotherapy beginning at least 4 weeks before study initiation are permitted to continue).
20. Subject has a history of severe allergies or adverse drug reactions to more than one class of medications.
21. Subject has a history of allergic reaction or a known or suspected sensitivity to methylphenidate or any substance that is contained in the study drug.
22. Subject, parent/legal guardian and caregiver (if applicable at the Investigator's discretion) has commitments during the study that would interfere with attending study visits.
23. Subject or subject's family anticipates a move outside the geographic range of the investigative site during the study or plans extended travel inconsistent with the recommended visit interval during study duration.
24. Subject has one or more siblings living in the same household who are enrolled in this or another clinical drug trial.
25. Subject shows evidence of current physical, sexual, or emotional abuse.
26. Subject is, in the opinion of the Investigator, unsuitable in any other way to participate in this study.
2. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances.
3. Subject has generalized anxiety disorder or panic disorder that has been the primary focus of treatment at any time during the 12 months prior to Screening, or that has required pharmacotherapy any time during the 6 months prior to Screening.
4. Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood (e.g., Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders), or history of persistent neurological symptoms attributable to serious head injury.
5. Subject taking anticonvulsants for seizure control currently or within the past 2 years before Screening are not eligible for study participation.
6. Subject has a current (last month) psychiatric diagnosis other than specific phobia, motor skills disorders, ODD, sleep disorders, elimination disorders, adjustment disorders, learning disorders, or communication disorders.
7. In the opinion of the Investigator, subject has clinically significant suicidal ideation/behavior, based on history of attempted suicide and the C-SSRS assessment at Screening.
8. Subject has any clinically significant unstable medical abnormality, chronic disease (including asthma or diabetes), or a history of a clinically significant abnormality of the cardiovascular (including cardiomyopathy, serious arrhythmias, structural cardiac disorders, or severe hypertension), gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion of study drug.
9. Subject has a history or presence of abnormal ECGs, which in the Investigator's opinion is clinically significant.
10. Subject has a history of, or currently has a malignancy.
11. Subject has uncontrolled thyroid disorder as evidenced by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the upper limit of normal (ULN) for the reference laboratory at Screening.
12. Subject has greater than trace proteinuria on the urinalysis at Screening.
13. A current or recent (past 12 months) history of drug abuse in someone living in the subjects' home.
14. Subject has a positive urine screen for drugs of abuse at Screening. If the urine test is positive for any of the analytes at Screening, the subject will be excluded from study participation, with the exception of the following: Depending on a subject's current ADHD medication at Screening, the urine screen may test positive for MPH for treatment of their ADHD.
15. Subject has participated in any other clinical study with an investigational drug/product within 30 days or at least 5 half-lives, whichever is longer, prior to Screening, except for participation in Study KP415.P01.
16. Subject has taken ADHD medications from more than one class within 30 days prior to Screening. Subjects on a stable dose of one ADHD medication with occasional use of ADHD medications from another class are eligible at the discretion of the Investigator.
17. Subject has demonstrated lack of response or intolerability to adequate dose and duration of treatment with methylphenidate products.
18. Subject is using or planning to use prohibited drugs during the trial as specified in the protocol.
19. Subject is planning to initiate psychotherapy during the study (subjects participating in psychotherapy beginning at least 4 weeks before study initiation are permitted to continue).
20. Subject has a history of severe allergies or adverse drug reactions to more than one class of medications.
21. Subject has a history of allergic reaction or a known or suspected sensitivity to methylphenidate or any substance that is contained in the study drug.
22. Subject, parent/legal guardian and caregiver (if applicable at the Investigator's discretion) has commitments during the study that would interfere with attending study visits.
23. Subject or subject's family anticipates a move outside the geographic range of the investigative site during the study or plans extended travel inconsistent with the recommended visit interval during study duration.
24. Subject has one or more siblings living in the same household who are enrolled in this or another clinical drug trial.
25. Subject shows evidence of current physical, sexual, or emotional abuse.
26. Subject is, in the opinion of the Investigator, unsuitable in any other way to participate in this study.
Minimum Eligible Age
4 Years
Maximum Eligible Age
5 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Premier Research Group plc
UNKNOWN
Sponsor Role
collaborator
Prometrika, LLC
INDUSTRY
Sponsor Role
collaborator
Almac
INDUSTRY
Sponsor Role
collaborator
Worldwide Clinical Trials
OTHER
Sponsor Role
collaborator
Corium, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ann Childress, MD
Role: PRINCIPAL_INVESTIGATOR
Center for Psychiatry And Behavioral Medicine Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Preferred Research Partners (PRP)
Little Rock, Arkansas, United States
Site Status
Advanced Research Center (ARC)
Anaheim, California, United States
Site Status
IMMUNOe International Research Center
Centennial, Colorado, United States
Site Status
Clinical Neuroscience Solutions - Orlando
Jacksonville, Florida, United States
Site Status
Accel Research Sites - Lakeland
Lakeland, Florida, United States
Site Status
Accel Research Sites - Maitland
Maitland, Florida, United States
Site Status
South Florida Research Phase I-IV INC
Miami Springs, Florida, United States
Site Status
CNS Healthcare - Orlando
Orlando, Florida, United States
Site Status
iResearch Atlanta
Decatur, Georgia, United States
Site Status
CenExel iResearch, LLC
Savannah, Georgia, United States
Site Status
Sky Clinical Research Network Group P.C.
Union City, Georgia, United States
Site Status
DelRicht Research - Touro Medical Center
New Orleans, Louisiana, United States
Site Status
St Charles Psychiatric Associates & Midwest Research Group
Saint Charles, Missouri, United States
Site Status
Boeson Research
Missoula, Montana, United States
Site Status
Alivation Research, LLC
Lincoln, Nebraska, United States
Site Status
Center For Psychiatry and Behavioral Medicine Inc
Las Vegas, Nevada, United States
Site Status
Clinical Neuroscience Solution, Inc
Memphis, Tennessee, United States
Site Status
Houston Clinical Trials
Bellaire, Texas, United States
Site Status
AIM Trials
Plano, Texas, United States
Site Status
Flourish Research
San Antonio, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KP415.P02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT03231800
COMPLETED
PHASE3
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
NCT02402166
COMPLETED
PHASE2
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
NCT05286762
COMPLETED
PHASE3
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
NCT05631626
COMPLETED
PHASE3
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00500071
COMPLETED
PHASE4
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT02734693
COMPLETED
PHASE3
Open-label Safety Study in Adults With ADHD
NCT02160262
COMPLETED
PHASE3
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
NCT03460652
COMPLETED
PHASE3
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT03327402
COMPLETED
PHASE1
Efficacy and Safety of SPD503 in Combination With Psychostimulants
NCT00734578
COMPLETED
PHASE3
Dasotraline Pediatric Extension Study
NCT02457819
COMPLETED
PHASE3
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
NCT02470234
COMPLETED
PHASE4
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
NCT02520388
COMPLETED
PHASE3
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01328756
COMPLETED
PHASE4
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
NCT02466386
COMPLETED
PHASE3
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
NCT03260205
COMPLETED
PHASE3
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
NCT07169162
WITHDRAWN
PHASE4
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
NCT00141050
COMPLETED
PHASE3
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
NCT00776009
COMPLETED
PHASE4
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
NCT00183391
COMPLETED
PHASE4
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
NCT00141063
COMPLETED
PHASE3
Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children
NCT00754208
COMPLETED
PHASE4
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
NCT03325894
TERMINATED
PHASE3
Long-Duration Stimulant Treatment Study of ADHD in Young Children
NCT00257725
COMPLETED
PHASE4